Allogene’s Phase 3 trial results continued to support the company’s “off-the-shelf” CAR-T strategy in large B-cell lymphoma. In an early analysis after 45 days of treatment, the company reported that 7 of 12 cema-cel recipients were negative for minimal residual disease compared with 2 of 12 placebo recipients. The company framed the MRD improvement as a potential predictor of delayed relapse, citing published thresholds for clinical differentiation. Allogene emphasized that the interim readout did not show severe immune or neurological adverse events typically associated with personalized CAR-T regimens, with most neurological effects described as low grade. Allogene is continuing enrollment of 220 participants, with 2027 expected reporting focused on relapse risk and the final efficacy determination.